The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer
|
|---|---|
| Published in |
Frontiers in oncology, January 2023
|
| DOI | 10.3389/fonc.2022.1057646 |
| Pubmed ID | |
| Authors |
Xingsheng Hu, Chunhong Hu, Xianling Liu, Fang Ma, Junpeng Xie, Ping Zhong, Chenxi Tang, Dan Fan, Yuan Gao, Xiang Feng, Mengge Ding, Dezhi Li, Chaoyuan Liu |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 6 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 1 | 17% |
| Researcher | 1 | 17% |
| Other | 1 | 17% |
| Student > Postgraduate | 1 | 17% |
| Unknown | 2 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 50% |
| Biochemistry, Genetics and Molecular Biology | 1 | 17% |
| Unknown | 2 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2023.
All research outputs
#17,874,215
of 26,171,302 outputs
Outputs from Frontiers in oncology
#8,270
of 22,919 outputs
Outputs of similar age
#279,014
of 485,479 outputs
Outputs of similar age from Frontiers in oncology
#500
of 1,392 outputs
Altmetric has tracked 26,171,302 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,919 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 485,479 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,392 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.